Miami-based health technology firm DermaSensor has solidified its trajectory in the competitive landscape of AI-driven oncology diagnostics. The company recently announced the successful closing of a $5 million extension to its Series B financing round. This latest injection of capital, which follows an initial $16 million Series B tranche finalized in October 2025, brings the total funding raised by the company to approximately $48 million.
The funding arrives at a pivotal juncture for the company, immediately following a flurry of commercial activity that saw the establishment of four key strategic partnerships. As DermaSensor continues to integrate its proprietary elastic scattering spectroscopy (ESS) technology into primary care settings, the company is positioning itself as a cornerstone provider for non-specialist clinicians tasked with early skin cancer detection.
Chronology: From Academic Concept to Market Reality
The journey of DermaSensor began in the research laboratories of Boston University, where the foundational technology—a fusion of AI and ESS—was conceptualized to address a critical gap in primary care: the subjective nature of visual skin lesion assessment.
The Development Roadmap
- Early Research & Development: Originating from academic research, the device underwent rigorous testing to prove its ability to analyze the cellular structure of skin lesions.
- January 2024: A major milestone was achieved when the US Food and Drug Administration (FDA) granted de novo clearance for the DermaSensor device. This authorization allowed for its use by primary care physicians and non-specialist clinicians to evaluate suspicious lesions, including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC).
- October 2025: The company closed its primary Series B financing round, raising $16 million to support its commercial rollout and operational scaling.
- June 2026: DermaSensor expanded its international footprint by securing CE marking in Europe, designated as a Class IIb medical device.
- September 1, 2026: The company announced four strategic partnerships, significantly broadening its distribution channels, including a critical supplier agreement with Henry Schein.
- September 2026: The company closed its $5 million Series B extension, bolstered by institutional support and a community-based funding campaign on Wefunder.
Strategic Infrastructure: The Power of Partnerships
The recent infusion of capital is inextricably linked to the company’s aggressive commercialization strategy. By securing four distinct partnerships in rapid succession, DermaSensor has effectively bypassed traditional, slow-moving distribution barriers.
The most notable of these, the supplier agreement with Henry Schein, provides DermaSensor with immediate access to a vast network of medical practices, positioning the device as a standard diagnostic tool in the primary care toolkit. Furthermore, the partnership with Medical Place—which serves as an exclusive reseller to the US Department of Veterans Affairs (VA)—ensures that the technology will reach a demographic with high clinical needs for dermatological screening.
These partnerships, coupled with a new customer agreement with a major US healthcare institution, are designed to create a "commercial infrastructure" that the company believes will lead to rapid adoption. By embedding itself into the workflows of large-scale healthcare networks, DermaSensor is moving beyond the "startup" phase and into the "infrastructure" phase of its corporate life cycle.
Supporting Data: Validating the AI Advantage
The efficacy of DermaSensor lies in its ability to translate complex spectral data into actionable insights for clinicians who may not have specialized dermatological training.
Clinical Efficacy and Performance
The device utilizes elastic scattering spectroscopy (ESS) to examine the cellular and sub-cellular organization of a lesion. When combined with the company’s proprietary AI algorithms, it provides an objective risk assessment. According to published clinical data:
- Sensitivity: The device has demonstrated a 96% sensitivity rate across the three most common skin cancers (melanoma, BCC, and SCC).
- Clinical Impact: In controlled studies, the use of the device has been shown to reduce missed skin cancer referrals by more than 50%. This metric is particularly vital in primary care, where the burden of screening falls on physicians who must differentiate between benign moles and potentially life-threatening malignancies.
The Scale of the Challenge
The urgency of this technology is underlined by current epidemiological trends. The Skin Cancer Foundation estimates that in 2026 alone, the US will see 234,680 new cases of melanoma. Of these, approximately 112,000 are categorized as invasive, while 122,680 are non-invasive. With one in five Americans affected by skin cancer at some point in their lives, the need for an accurate, accessible diagnostic tool is arguably one of the most pressing challenges in public health.
Official Perspectives: Democratizing Investment
The decision to pair institutional capital with a community-based Wefunder round is a strategic move that reflects CEO Cody Simmons’ vision for the company’s growth.
"Our professional investor partners have supported us through every phase of building this new medical device category," Simmons stated during the announcement. "Opening the financing on Wefunder is about extending that ownership to the physicians and patients who are living the problem we’re solving."
This approach serves two purposes: it provides necessary liquidity for scaling, and it creates a "base of advocates." By allowing clinicians and patients to hold a stake in the company, DermaSensor is creating a grassroots feedback loop. Physicians who are also shareholders are more likely to integrate the device into their practice, effectively turning the user base into a sales force.
Implications for the Future of Dermatology
The success of DermaSensor signals a broader paradigm shift in medical diagnostics: the decentralization of specialized care. By empowering primary care physicians to perform high-fidelity diagnostic assessments, the company is reducing the strain on specialized dermatologists and ensuring that patients receive faster, more accurate interventions.
Transforming the Primary Care Workflow
Currently, many skin lesions are referred to specialists "out of an abundance of caution," which can lead to long wait times and increased costs for the healthcare system. DermaSensor’s technology acts as a triage mechanism. By identifying low-risk lesions with high accuracy, it allows specialists to focus their expertise on high-risk patients who require biopsy and surgical intervention.
Regulatory and Market Resilience
With both FDA de novo clearance and the CE mark in Europe, DermaSensor has effectively cleared the primary regulatory hurdles that often sink early-stage diagnostic companies. The ability to navigate these complex regulatory environments, while simultaneously securing commercial partnerships, positions the company as a formidable player in the medical device sector.
Looking forward, the $48 million in total funding will likely be directed toward accelerating the integration of its software into electronic health records (EHRs) and expanding its sales force to capitalize on the new partnerships. As AI continues to integrate into the physician’s toolkit, DermaSensor is clearly betting that the future of oncology lies in the hands of the primary care provider, supported by data-driven, objective, and accessible diagnostic technology.
In a market where time is often the difference between a minor procedure and a life-altering diagnosis, the scalability of DermaSensor’s model suggests that the company is not just selling a device—it is building a new standard of care. With the current momentum, the coming fiscal year will be a critical test of how effectively this infrastructure can reduce the incidence of late-stage skin cancer diagnoses across the United States and beyond.
About the Author
